+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Increased cost sharing and changes in noncompliance with specialty referrals in The Netherlands



Increased cost sharing and changes in noncompliance with specialty referrals in The Netherlands



Health Policy 121(2): 180-188



The compulsory deductible, a form of patient cost-sharing in the Netherlands, has more than doubled during the past years. There are indications that as a result, refraining from medical care has increased. We studied the relation between patient cost-sharing and refraining from medical care by evaluating noncompliance with referrals to medical specialists over several years. Noncompliance with specialty referrals was assessed in the Netherlands from 2008 until 2013, using routinely recorded referrals from general practitioners to medical specialists and claims from medical specialists to health insurers. Associations with patient characteristics were estimated using multilevel logistic regression analyses. Noncompliance rates were approximately stable from 2008 to 2010 and increased from 18% in 2010 to 27% in 2013. Noncompliance was highest in adults aged 25-39 years. The increase was highest in children and patients with chronic diseases. No significantly higher increase among patients from urban deprived areas was found. Noncompliance increased during the rise of the compulsory deductible. Our results do not suggest a one-to-one relationship between increased patient cost-sharing and noncompliance with specialty referrals. In order to develop effective policy for reducing noncompliance, it is advisable to focus on the mechanisms for noncompliance in the groups with the highest noncompliance rates (young adults) and with the highest increase in noncompliance (children and patients with chronic diseases).

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059849419

Download citation: RISBibTeXText

PMID: 27989512

DOI: 10.1016/j.healthpol.2016.12.001


Related references

Link between cost-sharing, noncompliance cited. Managed Care 12(10): 52-52, 2003

High-Cost, High-Value Oral Specialty Drugs: More Evidence on the Impact of Cost Sharing in Medicare Part D. Journal of Clinical Oncology 34(36): 4307-4309, 2016

Same-specialty referrals for imaging compared with referrals to radiologists: are the data correct?. Radiology 247(2): 592; Discussion 592, 2008

Using clinically nuanced cost sharing to enhance consumer access to specialty medications. American Journal of Managed Care 20(6): E242-E244, 2014

Impact of Cost-Sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study. Health Services Research 53(Suppl. 1): 2735-2757, 2018

Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis. Health Services Research 45(5 Pt 1): 1227-1250, 2010

The redesign of consumer cost sharing for specialty drugs at the California Health Insurance Exchange. American Journal of Managed Care 22(4 Suppl): S87-S91, 2016

Impact of cost sharing on specialty drug utilization and outcomes: a review of the evidence and future directions. American Journal of Managed Care 22(3): 188-197, 2016

Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis. Arthritis and Rheumatism 61(6): 745-754, 2009

PCTs struggle to cope with cost of increased referrals. Health Service Journal 118(6136): 10, 2008

Cost Sharing Does Not Lead to an Overall Increase of Involuntary Commitments in the Netherlands. JAMA Psychiatry 75(2): 213, 2018

Cost Sharing and Mental Health Care: A Cautionary Tale From the Netherlands. JAMA Psychiatry 74(9): 940-941, 2017

Specialty Tier-Level Cost Sharing and Biologic Agent Use in the Medicare Part D Initial Coverage Period Among Beneficiaries With Rheumatoid Arthritis. Arthritis Care & Research 68(11): 1624-1630, 2016

Impact of cost sharing increases under part D specialty tiers on Biologic adherence and discontinuation among Medicare Beneficiaries with multiple Sclerosis or Rheumatoid Arthritis. Value in Health 18(3): A79-A80, 2015

High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia. American Journal of Managed Care 22(4 Suppl): S78-S86, 2016